Showing results (111-120 of 386) with videos related to
Sort By:
Pageof 39
Cancer Immunology, Immunotherapy : CII|July 19, 2019
Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockadeJun Zhou, Jingjing Li, Indira Guleria, et al.Proceedings of the National Academy of Sciences of the United States of America|May 2, 2002
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destructionF Stephen Hodi, Jan C Schmollinger, Robert J Soiffer, et al.Oncoimmunology|October 10, 2015
A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumabRavi A Chandra, Tyler J Wilhite, Tracy A Balboni, et al.JAMA|November 5, 2014
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trialF Stephen Hodi, Sandra Lee, David F McDermott, et al.Cancer Medicine|October 18, 2016
A phase I trial of panobinostat (LBH589) in patients with metastatic melanomaNageatte Ibrahim, Elizabeth I Buchbinder, Scott R Granter, et al.Nature Clinical Practice. Oncology|July 31, 2008
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNSF Stephen Hodi, Darryl A Oble, Jan Drappatz, et al.Journal of Proteome Research|March 4, 2008
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancerKaren S Anderson, Niroshan Ramachandran, Jessica Wong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2016
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical CourseMizuki Nishino, Nikhil H Ramaiya, Mark M Awad, et al.Cancer Immunology, Immunotherapy : CII|January 22, 2021
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitorsKevin Tyan, Joanna Baginska, Martha Brainard, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaJedd D Wolchok, Axel Hoos, Steven O'Day, et al.Pageof 39